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Abstract. Wilson disease (WD) is an autosomal recessive disorder caused by mutations in the ATP7B gene, 
yet many patients have either one mutation, or no mutation. We investigated whether the mutation 
detection rate is associated with any biochemical characteristics of WD. In a study of 71 patients, we used 
PCR-sequencing to screen for ATP7B mutations in 7 exons (exons 8, 10, 11, 14, 15, 16, and 18) covering 
95% of known mutations in Korean patients with WD. We also investigated serum concentrations of 
various biochemical analytes. Data were analyzed by linear association test and one-way ANOVA. Based 
on the number of detected ATP7B mutations, a significant difference in serum ceruloplasmin concentration 
was found among the 3 groups (p <0.001). Serum ceruloplasmin concentration averaged 3.32 ± 1.74, 10.8 
± 5.50, and 14.9 ± 3.88 mg/dl (mean ± SD) in the 25, 20, and 26 patients with two, one, and no ATP7B 
mutations, respectively. We observed 82.9% and 16.7% of mutant allele frequency in WD patients with 
ceruloplasmin concentration <10 mg/dl and 10-20 mg/dl, respectively (p <0.001). Thus serum ceruloplasmin 
concentrations among WD patients differed according to the number of ATP7B mutations detected. 
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Introduction 
 
Wilson disease (WD; MIM #277900) is a disorder 
of copper (Cu) metabolism [1]. Liver disease, 
neurologic presentations, and psychiatric 
disturbances are caused by an accumulation of Cu. 
The age of affected individuals varies from 3 to >50 
yr. Worldwide prevalence of WD appears to be 
about 30 per 1 million, with a gene frequency of 
0.56% and a carrier frequency of 1 in 90 [2,3]. 
However, the incidence of WD in Korea may be 
higher than that in Western populations, given the 
report of a Korean family with WD in two 
consecutive generations [4]. 
 Diagnosis of WD usually depends on detection 
of low serum Cu and ceruloplasmin concen-
trations, increased urinary Cu excretion, presence 
of Kayser-Fleischer rings in the cornea, and/or 
increased hepatic Cu concentration. No single 
feature is completely reliable, but a diagnosis can 
usually be made provided that WD is suspected 
[2,3,5]. There is no worldwide consensus on a 
definitive diagnostic tool, but elevated liver Cu 
concentration is important for confirmation of 
WD [6,7]. WD is caused by mutations in the 
ATP7B gene, which encodes a Cu-transporting P-
type ATPase. More than 379 probable disease-
causing mutations from populations worldwide 
have been reported [8]. Because WD is an autosomal 
recessive disorder, most WD patients have two 
ATP7B mutations. Mutation analysis may be useful 
in cases with unclear liver disease [9]. However, 
many WD patients have either one ATP7B mutation 
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or no mutation. Direct sequencing of all 21 ATP7B 
exons and their adjacent introns from 120 Korean 
WD patients showed a mutation detection rate of 
75.0% (180/240), and about 95% of mutations 
were identified within 7 exons (exons 8, 10, 11, 14, 
15, 16, and 18) [10]. About 25% of mutant alleles 
had not been previously identified in Korean 
patients with WD [10,11]. With an autosomal 
recessive disorder, patients with either one mutation 
or no mutation in the ATP7B gene may have point 
mutations in the other 14 exons, a large deletion or 
duplication, mutations in promoter regions, 
presence of gene rearrangements, or possible 
mutations in Cu-transport chaperone genes, such 
as ATOX1 and COMMD1 [12-14]. However, there 
is no evidence of a large deletion or duplication in 
WD patients with either one ATP7B mutation or 
no mutation (unpublished data). Therefore, we 
tried to uncover differences in the biochemical 
characteristics of patients with WD according to 
the number of ATP7B mutations detected.
Materials and Methods
Seventy-one patients were recruited for the present study 
(median age 21.0 yr, range 4~49 yr). Sixty-nine patients were 
unrelated and two were sisters of two patients. Patients had 
received a diagnosis of WD based on clinical, biochemical, 
and molecular analyses; at least two positive findings were 
observed for the following characteristics: presence of Kayser-
Fleischer rings in the cornea, increased Cu concentration in 
24-hr urine or liver tissue, and decreased serum ceruloplasmin. 
In addition, many patients presented with hepatic symptoms, 
signs of increased serum alanine aminotransferase (ALT) or 
aspartate aminotransferase (AST) activities, and neurologic 
symptoms, such as movement disorders. Various biochemical 
parameters were analyzed, including ceruloplasmin, Cu, 
ALT, AST, alkaline phosphatase, and albumin, as well as viral 
markers, including HBs Ag, anti-HBs Ab, and anti-HCV 
using either the Hitachi 7600-110 analyzer (Hitachi, Tokyo, 
Japan), Roche Modular E170 analyzer (Roche Diagnostics, 
Basel, Switzerland), or the ADVIA Centaur immunoassay 
system (Siemens Healthcare Diagnostics, Deerfield, IL, 
USA). This study was approved by the Institutional Review 
Board at Samsung Medical Center.
 We used PCR-sequencing to investigate molecular 
defects in the ATP7B gene in patients. Genomic DNA was 
extracted from peripheral blood using a Wizard genomic 
DNA purification kit (Promega, Madison, WI) after obtaining 
informed consent from either patients or their parents. 
Mutation screening was performed for 7 exons (exons 8, 10, 
11, 14, 15, 16, and 18) representing 95% of exons containing 
mutations found in Korean patients with WD [10]. Forward 
and reverse primers for genomic DNA sequencing were 
designed to amplify the 7 coding exons (primer sequences 
available upon request). Sequencing was carried out using the 
BigDye terminator cycle sequencing kit, and products were 
resolved on an ABI 3100 Genetic Analyzer (Applied 
Biosystems, Foster City, CA, USA). Data were analyzed by 
linear association test and one-way ANOVA. All significance 
tests were two-tailed, and p values <0.05 were considered 
significant. All statistical analyses were carried out using the 
SPSS 12.0 statistical software (SPSS, Chicago, IL, USA).
Results 
We identified 70 ATP7B mutations in Korean 
patients with suspected WD. When patients were 
classified into three groups according to the number 
of ATP7B mutations, 25 patients had two mutations 
(homozygous or compound heterozygous), and 20 
had one mutation. The other 26 patients had no 
mutation in 7 ATP7B exons (Table 1). Patients with 
Table 1. Biochemical findings in patients with suspected Wilson disease.
ATP7B No.  Serum cerulo- Urine Cu* Liver Cu* Serum AST* Serum ALT* Serum
mutations of  plasmin† (µg/day) (µg/g dry wt) (U/L) (U/L) albumin*
   subjects  (mg/dl)     (g/dl)
   reference range: 20-60 <38 <50 <40 <40 3.5-5.2
 2 25 Mean 3.32 443.7 293.5 64.0 113 3.99
   SD 1.74 419.3 380.2 40.3 103 0.42
   Range 1.7-7.8 89-1525 32-857 14-140 12-371 2.8-4.5
 
 1 20 Mean 10.8 368.6 226.2 65.3 125 4.16
   SD 5.50 539.5 287.5 43.9 93.1 0.45
   Range 2.1-18.3 14-1697 39-919 12-164 8-297 2.6-4.8
 
 0 26 Mean 14.9 192.7 125.5 70.0 112 3.92
   SD 3.88 217.8 108.4 77.9 152 0.72
   Range 3.5-19.9 43-982 34-304 16-331 12-615 2.0-4.9
† p < 0.001; * not significant
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HBs Ag or anti-HCV were not observed. With the 
exception of ceruloplasmin, other clinical or 
biochemical characteristics among the three groups 
were not significantly different. Serum cerulo-
plasmin concentrations (mean ± SD, mg/dl) were 
3.32 ± 1.74, 10.8 ± 5.50, and 14.9 ± 3.88 in patients 
with two, one, and no ATP7B mutations, 
respectively. Significant differences were observed 
in serum ceruloplasmin concentrations among the 
three patient groups (p <0.001) (Fig. 1).
Discussion
A scoring system based on a combination of clinical 
symptoms and laboratory test results was proposed 
for assessment of the diagnostic accuracy of WD 
[15]. However, even the most sensitive and specific 
laboratory tests are secondary to astute clinical 
suspicion in the search for WD [16]. Correct 
diagnosis of WD requires strong clinical suspicion 
and adequate laboratory testing. About 85% of 516 
Korean patients with WD have demonstrated 
hepatic symptoms [17], similar to the results of the 
present study. Because hepatitis B is endemic to 
Korea, HBs Ag and anti-HBs Ab tests are preferred 
for Korean patients with hepatic symptoms [18]. 
WD should be suspected in patients with abnormal 
liver function who test positive for anti-HBs Ab. 
Although elevated urinary Cu excretion resulting 
from release of Cu from necrotic hepatocytes has 
been reported in other forms of acute liver failure, 
urinary Cu excretion is significantly elevated in 
patients with fulminant WD [19]. 
 In comparison to other available tests, including 
serum alkaline phosphatase, bilirubin, and  amino-
transferases, conventional WD tests utilizing serum 
ceruloplasmin and/or serum Cu concentration are 
less sensitive and specific for identification of 
patients with acute liver failure due to WD [20]. 
Ceruloplasmin deficiency can also be seen in other 
pathological conditions, including Menkes’ disease, 
protein calorie malnutrition, nephrotic syndrome, 
protein-losing enteropathy, acquired Cu deficiency, 
severely impaired hepatic synthetic function, and 
hereditary aceruloplasminemia [16]. However, 
ceruloplasmin deficiency is a key finding in the 
diagnostic approach to WD because there is no 
single definitive test for diagnosis of WD. A 
Table 2. The ATP7B mutant allele frequency was associated with serum ceruloplasmin concentration in WD patients. 
  Ceruloplasmin <10 mg/dl  Ceruloplasmin 10-20 mg/dl
No. of ATP7B mutations  2 1 0 2 1 0
No. of patients 25 8 2 0 12 24
No. of total mutant alleles  50 (12*)  8 (6*) 0 0 12 (5*) 0
Mutant allele frequency (%)† 82.9   16.7
† p < 0.001; * No. of unique mutant alleles
Fig. 1. Serum ceruloplasmin concentrations in WD patients. 
Patients with two, one, and no ATP7B mutations were 
classified into groups 1, 2 and 3, respectively. Mean 
ceruloplasmin concentrations in groups 1, 2, and 3 were 
3.32, 10.8, and 14.9 mg/l, respectively. There was a significant 
difference of ceruloplasmin concentrations between groups 1 
and 2 (p < 0.001) and between groups 2 and 3 (p = 0.005).
  A significant difference was observed in mutant 
allele frequency according to serum ceruloplasmin 
concentrations in patients with WD (Table 2). We 
observed 82.9% and 16.7% mutant allele frequency 
in WD patients with ceruloplasmin concentrations 
<10 and 10-20 mg/dl, respectively (p <0.001).
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ceruloplasmin concentration of <20 mg/dl is the 
conventional diagnostic cutoff for WD. One report 
demonstrated a ceruloplasmin concentration of 
<10 mg/dl in 72.7% of patients with WD, but the 
ceruloplasmin concentration in 9.1% of patients 
with WD was >21 mg/dL [21]. However, another 
study recently reported that modification of the 
decision threshold of serum ceruloplasmin from 20 
mg/dl to 14 mg/dl increases diagnostic accuracy for 
Wilson disease [22]. In the present study, all WD 
patients with two ATP7B mutations had serum 
ceruloplasmin concentrations <10 mg/dL. Cerulo-
plasmin concentrations in WD patients with two 
ATP7B mutations were severe and attenuated 
compared to patients with no mutation. 
 The 2006 Mayo Clinic study on use of dried 
blood spots for WD screening concluded that while 
screening for WD by testing for blood ceruloplasmin 
appears desirable, larger studies would be needed to 
determine sensitivity, specificity, effectiveness, and 
efficacy of screening [23]. Therefore, patients with 
mild, attenuated ceruloplasmin concentrations 
who also have other characteristics of WD require 
thorough evaluation in order to determine whether 
they are patients or carriers of WD. In particular, 
we found a wide distribution of serum ceruloplasmin 
concentrations in 20 patients with one ATP7B 
mutation. In these patients, WD may be attributed 
to a point mutation in an uncovered exon or to 
another pathogenic mechanism. These patients 
presented with ceruloplasmin reduction and no 
other condition. 
 If left untreated, WD is a potentially lethal 
disorder. Early diagnosis of WD is important, 
because early administration of D-penicillamine 
can prevent the need for transplantation in most 
cases [24]. Some anticopper drugs, including 
penicillamine, zinc, and trientine, have been used, 
and various management protocols are available to 
WD patients, depending on the type and severity 
of symptoms [25]. Cu chelation requires life-long 
compliance; therefore, prompt, accurate diagnosis 
of WD is important. WD carriers often have no 
clinical symptoms, so no treatment is  necessary. 
 In summary, we investigated the relationship 
between biochemical and molecular characteristics 
in WD patients. Ceruloplasmin concentrations 
differed significantly, depending on the number of 
ATP7B mutations, and mutation detection rate was 
associated with ceruloplasmin concentration. 
Because only a limited number of patients were 
studied, these results contribute little to the use of 
ceruloplasmin for screening purposes. However, 
these findings suggest that another mechanism 
may be the cause of WD in patients with less than 
two ATP7B mutations. Further study will be 
necessary to confirm or refute this hypothesis. 
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